The macrophage electrophoretic mobility (MEM) test was introduced in 1970 as a method for the detection of cancer (Field & Caspary, 1970) . The procedure can be described briefly as follows. Peripheral-blood mononuclear cells are incubated with an "antigen" preparation, and as a second step the supernatant of the first incubation is incubated with indicator cells. The electrophoretic mobility of the indicator cells was reported to depend on whether the mononuclear cells were prepared from the blood of healthy controls or from cancer patients. The test has been used by different groups with several modifications (reviewed by Mross, 1981) . Brain extract, homogeneous preparations of myelin basic protein MBP (= encephalitogenic factor EF) or extracts from cancer tissue have been used as "antigens" (e.g. Dyson & Corbett, 1978; Muller et al., 1977) ; macrophages as indicator cells have been substituted by sheep erythrocytes tanned and stabilized with sulphosalicylic acid (ETS) (Porzsolt et al., 1975) . Whatever the modifications, the results are contradictory: some investigators claim to detect differences in the response of healthy subjects and cancer patients; others cannot reproduce these findings (reviews by Porzsolt, 1978; Mross & Wolfrum, 1980 (Dyson, 1979; Schumacher & Grol, 1981) . If the latter is true it should be possible to simplify the test and to avoid the technical problems of cell electrophoresis by monitoring directly the interaction between mononuclear cells and antigen.
MATERIALS AND METHODS
Selection of subjects.-At this stage of the investigation our main object was to try to determine a difference between normal control subjects and cancer patients. We did not discriminate between different forms of cancer.
Preparation of mononuclear cells.-Human peripheral blood was defibrinated or heparinized and the mononuclear cells were prepared by standard procedures using Ficoll-Hypaque (Seromed) as the separation medium. The cells were washed thoroughly to ensure that no serum was retained in the preparations. Hanks' balanced salt solution (HBSS) was used for the final suspensions of the cells. Besides lymphocytes the preparations contained about 10-15% monocytes. For some experiments the mononuclear cells were activated before incubation with MBP. This was done by incubating 3 x 106 cells in 1 ml RPMI (Flow Laboratories), 5% foetal calf serum (FCS), 2% penicillin/streptomycin (PS) with PHA or TPA in concentrations as indicated in Fig. 4 for 24 h at 37°C under an atmosphere containing 5% CO2. The cells were washed x 3 with 5 ml RPMI and resuspended in 1 ml RPMI containing MBP.
Preparation of MBP.-Bovine and human MBP were prepared as described by Pitts et al. (1976) . Part of the bovine MBP was a gift from Dr Wolfrum's group, Gottingen. The preparations were more than 9500 pure as judged by SDS-PAGE.
Radioiodination of MBP.-The radioiodination of MBP was carried out according to Bolton (1977) using Chloramin-T. 100 ,ug MBP was mixed with 50 ,tCi NaI251 (Amersham Buchler). After adding 3 mg MBP in HBSS, 1251-MBP was separated from unreacted Na1251 by gel filtration using a PD-10 column (Pharmacia) equilibrated with HBSS.
After filtration through a 0 24tm membrane (Acrodisc, Gelman) the sterile solution was stored at 4°C at a concentration of 1 mg 125L-MBP/ml HBSS. The specific activity was 2-6 x 105 ct/min/,ug protein. The purity of 1251-MBP was analysed by SDS-PAGE as described below and thin-layer chromatography. Cellulose plates (Merck) were run in n-butanol/pyridine/acetic acid/bi-distilled water (60:40:12:48 v/v) . No loss of iodine could be detected during the experimental period.
Sample preparation. If not stated otherwise, 3 x 106 mononuclear cells/ml were incubated with 120 ,ug/ml = 6-5 x 10-6M MBP at 37TC using HBSS or, in the case of prolonged incubation, RPMI as buffer. Aliquots were taken at various times as indicated in the figures. Proteolysis was stopped in different ways, depending on the subsequent analytical procedure (v.i.) . MBP incubated with buffer alone and mononuclear cells without added antigen were used as controls.
Electrophoresis.-Polyacrylamide gels at 12, 15 and 20% were prepared according to Weber & Osborn (1969) or Lammli (1970) . Aliquots of the radioactive incubation mixtures were mixed with 5 ,ul of a bromophenol blue solution and applied on to the gels. The radioactive protein bands were localized by autoradiography. cut out and the activity determined in a gamma counter. The percentage of cleaved product was calculated and corrections were made for nonspecific degradation in the absence of mononuclear cells. Nonradioactive incubation mixtures were centrifuged before application on to the gels. Protein bands were detected by staining with Coomassie Brilliant Blue R 250.
Gel filtration.-Aliquots of the supernatants of the incubation mixture were separated by gel filtration using Ultrogel AcA 202 (LKB), which has a fractionation range of 1000 to 15,000 mol. wt. Fractions of 20 drops eluted from a column (1 1 x 35 cm) equilibrated with 0-5M NaCl, 01M Tris/HCl (pH 8.0) at room temperature were collected and counted for radioactivity.
Binding of MBP to mononuclear cells.-MBP and mononuclear cells (for concentrations see Fig. 6 ) were incubated at room temperature in HBSS with additional bovine serum albumin (2 mg/ml) to avoid clumping of the cells during the subsequent centrifugation. Separation of the cells from unbound MBP was achieved as described by Pingoud et al. (submitted) . Briefly, aliquots were layered on top of silicon oils AR 20 and AR 200 (Wackerchemie). The tubes were centrifuged for 15 s in a model 5120 Eppendorf centrifuge, frozen in liquid N2 and cut into 2 parts. The radioactivity in the sediment and supernatant was measured to calculate the percentage of MBP bound to mononuclear cells. The layer of silicon oil between sediment and supernatant showed no radioactivity.
RESULTS
The time course of the degradation of MBP can be subdivided into 2 parts. A rapid degradation to peptides of mol. wts 9000-14,000 was followed by a slower degradation to products of mol. wts * 5000. The time course of the proteolytic degradation and the size of the products are the same for MBP from human and bovine brain. This was expected from a comparison of the aminoacid sequences of the proteins from the 2 species (Dunkley & Carnegie, 1974) . They are identical in the regions of preferential cleavage. The products of the fast degradation can be analysed by gel electrophoresis. The smaller peptides resulting from the slower degradation cannot conveniently be detected electrophoretically, and gel chromatography was used as the analytical method instead.
Characterization of the fast proteolytic degradation
The mol. wts of the degradation products formed during the first 2 h of incubation were determined in the Lammli electrophoresis system. The first component appearing has mol. wt 14,000, followed by 1 or 2 components of 9000-11,000. After 20-24 h of incubation these products are still detectable, though there is no intact MBP left. There is an apparent loss of protein because smaller peptides cannot be stained in this system. The observed fragmentation pattern agrees with the results of Bergstrand (1971) , who carried out a more extensive characterization of the resulting peptides.
With a given amount of antigen the proteolytic degradation is dependent on the concentration of mononuclear cells. Therefore all cleavage data were related to mononuclear cell concentration, which varied in different experiments. In order to locate the proteolytic activity, mononuclear cells were preincubated in HBSS, (Fig. 4) . It seems unlikely, therefore, that the slow degradation is due to lysosomal enzymes secreted upon cell lysis after prolonged incubation.
Comparison of healthy controls and cancer patients
The blood samples of 6 healthy controls were compared to those of 12 cancer patients. The quantity of fragments with mol. wts < 1000 was taken as a measure of proteolysis (Fig. 5) . The degree of degradation varies widely even within the control samples, but is not different for Tautz et al., 1977) . During this incubation, MBP is degraded by a proteolytic activity associated with the mononuclear cells. It is not clear, however, where the proteolysis is located on the cells or which species of the mononuclear cells is responsible for the effects. One can distinguish a fast degradation during the first hours of incubation leading to a fragmentation of MBP to products containing more than the half of the original molecule, and a slower process leading to peptides of mol. wt 5000 and less.
The duration of the proteolysis is dependent on incubation conditions, mononuclear-cell and protein concentrations, and varies from patient to patient. This may be due in part to the inhomogeneity of the mononuclear cells.
Irrespective of these difficulties, there is clearly no detectable difference between cancer patients and healthy controls, in the proteolytic activity ofperipheral-blood mononuclear cells. Our results are somewhat at variance with those published by Fish et al. (1974) What cannot be excluded by these studies is the possibility that the small amount of bound MBP could lead to a different production of a lymphokine in cancer patients and healthy controls. One consideration argues against this hypothesis, at least as a possible mechanism of the EMT. To get a 10% reduction of the electrophoretic mobility of the ETS by MBP, a highly basic protein, a concentration of at least 30 ,ug/ml protein is needed (Buurmann, unpublished result). This amount of protein (1 jug per aliquot) is easily detected in our electrophoretic system. During all our electrophoretic investigations we could never detect even traces of a newly appearing protein, such as a lymphokine, that might influence electrostatically the ETS (dead cells which cannot respond physiologically).
Though our data may not be representative statistically, they indicate that the binding reaction between MBP and lymphocytes and the lymphocyte-associated proteolytic activity towards MBP, are unsuitable for the detection of cancer. They furthermore show that the 2 most obvious explanations for the claimed specificity of the EMT and MEM test as a cancer test can be excluded. This result, and the accumulating negative experience with the MEM test and the EMT as a diagnostic tool (e.g. Hoffmann et al., 1981) make us suspect that there is no rational basis for the MEM test/EMT as a procedure for detecting cancer in humans.
